Literature DB >> 26206336

Intrapulmonary Delivery of CpG Microparticles Eliminates Lung Tumors.

Takashi Sato1, Takeshi Shimosato2, Atsuhisa Ueda3, Yoshiaki Ishigatsubo3, Dennis M Klinman4.   

Abstract

CpG oligonucleotides (ODN) stimulate the innate immune system by triggering cells that express TLR9. The resulting response promotes tumor regression, an effect optimized by delivery of CpG ODN to the tumor site. This work examines the effect of instilling CpG ODN adsorbed onto polyketal microparticles (CpG-MP) into the lungs of mice with non-small cell lung cancer. Intrapulmonary delivery of CpG-MP improved ODN uptake and retention at the tumor site, thereby inducing a stronger Th1 response than systemically administered or unadsorbed CpG ODN. CpG-MP reversed the immunosuppression that characterized the tumor microenvironment by (i) decreasing the number of immunosuppressive Tregs and M2 macrophages while (ii) increasing the number of tumoricidal CD8(+) T cells and M1 macrophages. These effects promoted tumor regression and culminated in 82% permanent survival of mice with otherwise fatal Lewis lung cancer. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26206336      PMCID: PMC4596766          DOI: 10.1158/1535-7163.MCT-15-0401

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  47 in total

Review 1.  Immunotherapeutic uses of CpG oligodeoxynucleotides.

Authors:  Dennis M Klinman
Journal:  Nat Rev Immunol       Date:  2004-04       Impact factor: 53.106

Review 2.  Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications.

Authors:  N R Labiris; M B Dolovich
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

3.  Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination.

Authors:  Chiara Nembrini; Armando Stano; Karen Y Dane; Marie Ballester; André J van der Vlies; Benjamin J Marsland; Melody A Swartz; Jeffrey A Hubbell
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-03       Impact factor: 11.205

Review 4.  Surgery of the primary in stage IV colorectal cancer with unresectable metastases.

Authors:  Comelis Verhoef; Johannes H de Wilt; Jacobus W A Burger; Henk M W Verheul; Miriam Koopman
Journal:  Eur J Cancer       Date:  2011-09       Impact factor: 9.162

5.  Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells.

Authors:  Yuko Shirota; Hidekazu Shirota; Dennis M Klinman
Journal:  J Immunol       Date:  2012-01-09       Impact factor: 5.422

6.  NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides.

Authors:  Y Kawarada; R Ganss; N Garbi; T Sacher; B Arnold; G J Hämmerling
Journal:  J Immunol       Date:  2001-11-01       Impact factor: 5.422

7.  Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model.

Authors:  Klaus Heckelsmiller; Katharina Rall; Sebastian Beck; Angelika Schlamp; Julia Seiderer; Bernd Jahrsdörfer; Anne Krug; Simon Rothenfusser; Stefan Endres; Gunther Hartmann
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

8.  Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides.

Authors:  Jonathan Baines; Esteban Celis
Journal:  Clin Cancer Res       Date:  2003-07       Impact factor: 12.531

9.  Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity.

Authors:  Anke S Lonsdorf; Haydar Kuekrek; Britta V Stern; Bernhard O Boehm; Paul V Lehmann; Magdalena Tary-Lehmann
Journal:  J Immunol       Date:  2003-10-15       Impact factor: 5.422

10.  Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical.

Authors:  T Tatsumura; S Koyama; M Tsujimoto; M Kitagawa; S Kagamimori
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

View more
  7 in total

Review 1.  Inhalation of sustained release microparticles for the targeted treatment of respiratory diseases.

Authors:  Gauthami Pulivendala; Swarna Bale; Chandraiah Godugu
Journal:  Drug Deliv Transl Res       Date:  2020-04       Impact factor: 4.617

2.  Pulmonary Delivery of Nanoparticle-Bound Toll-like Receptor 9 Agonist for the Treatment of Metastatic Lung Cancer.

Authors:  Jillian L Perry; Shaomin Tian; Nisitha Sengottuvel; Emily B Harrison; Balachandra K Gorentla; Chintan H Kapadia; Ning Cheng; J Christopher Luft; Jenny P-Y Ting; Joseph M DeSimone; Chad V Pecot
Journal:  ACS Nano       Date:  2020-06-02       Impact factor: 15.881

Review 3.  Use of nanoparticles to deliver immunomodulatory oligonucleotides.

Authors:  Dennis M Klinman; Takashi Sato; Takeshi Shimosato
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2015-12-12

4.  Effect of Calcium Carbonate Encapsulation on the Activity of Orally Administered CpG Oligonucleotides.

Authors:  Neslihan Kayraklioglu; Julia Scheiermann; W Gregory Alvord; Dennis M Klinman
Journal:  Mol Ther Nucleic Acids       Date:  2017-06-23       Impact factor: 8.886

5.  Codon-Optimized P1A-Encoding DNA Vaccine: Toward a Therapeutic Vaccination against P815 Mastocytoma.

Authors:  Alessandra Lopes; Kevin Vanvarenberg; Véronique Préat; Gaëlle Vandermeulen
Journal:  Mol Ther Nucleic Acids       Date:  2017-07-13       Impact factor: 8.886

Review 6.  Silicosis and lung cancer: current perspectives.

Authors:  Takashi Sato; Takeshi Shimosato; Dennis M Klinman
Journal:  Lung Cancer (Auckl)       Date:  2018-10-26

Review 7.  Vaccine adjuvants as potential cancer immunotherapeutics.

Authors:  Burcu Temizoz; Etsushi Kuroda; Ken J Ishii
Journal:  Int Immunol       Date:  2016-03-22       Impact factor: 4.823

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.